Poor adherence is one of the main reasons for inadequate control of hypertension and dyslipidemia (DLP). This is especially true for patients with hypertension and DLP and no clinical manifestations of atherosclerosis. Objective - to study the possibility of enhancing medication adherence in high risk patients with hypertension and DLP by means of an electronic SCORE version. Patients and methods. The investigation enrolled 140 male and female patients aged 40 to 65 years with hypertension and DLP who had sought for medical advice in a primary health facility - the polyclinic of Clinical Hospital One (Moscow). The patients had mild and moderate hypertension (systolic blood pressure (BP) 140-179 mm Hg; diastolic BP 90-104 mm Hg) and DLP (total cholesterol was more than 5.0 mmol/l) and no coronary heart diseases or other clinical manifestations of atherosclerosis. All the patients included into the investigation had a high SCORE risk (5% or more). They had received no antihypertensive therapy or had been treated irregularly. Adequate antihypertensive and hypolipidemic therapy was performed in all the included patients as high risk ones. Moreover, all the patients were given advice about healthy lifestyle (smoking cessation, healthy diet, and increased exercise). After signing a voluntary informed consent form, the patients (n=140) were randomized into two equal groups (a study group and a control group). For overall risk assessment, electronic and tabular SCORE versions were used in the study (n=70) and control (n=70) groups, respectively. In the study group, in addition to overall risk assessment, the main outcome measures were positive risk changes when achieving the target levels of BP and total cholesterol and smoking cessation. The investigation lasted 6 months. Results. Analysis of adherence to antihypertensive and lipid-lowering medications showed that there was considerable compliance in the group of patients whose risk was assessed using the electronic SCORE version. At 6 months after treatment, 46 (65.7%) study patients and 35 (50.0%) control patients remained on antihypertensive therapy (p<0.05). There were substantial differences in compliance with lipid-lowering therapy between the study and control groups. By the end of the investigation, 42 (60.0%) study patients and only 12 (17.1%) controls continued to take lipid-lowering drugs. The group differences were significant (p<0.001). Conclusion. Our findings suggest that the use of the electronic SCORE version makes it possible not only to rapidly assess an overall risk in a patient, but also to enhance adherence to antihypertensive and lipid-lowering medications in the patients who make no complaints (risk factors do not hurt) and are unmotivated in treatment. Thus, the integration of the electronic SCORE version into clinical practice may be an effective approach to enhancing medication adherence and to reducing cardiovascular risk.